UNLABELLED: The outcome of hepatitis C virus (HCV) infection has been associated with antiviral CD4 T cell response, human leukocyte antigens (HLA) class II genotypes, and ethnicity. However, HLA class II molecules restrict the nature of CD4 T cell response, and HLA distributions differ between ethnic groups. In this study, we asked whether HLA class II genotypes associated with HCV clearance are shared between Caucasian and African Americans and whether they contribute to enhanced antiviral CD4 T cell response. In a cohort of 93 HCV-seropositive subjects from Northeast America with defined ethnicity, virological outcome, and HCV-specific CD4 T cell proliferation, we confirm the previously reported associations between HCV clearance and two HLA types (DQB1*03, DRB1*11) while identifying a new association with DRB3*02. Strikingly, these associations were identified only among Caucasian [DQB1*03: odds ratio (OR), 10.4; P = 0.031, DRB1*11: OR, 7.0, P = 0.019; DRB3*02: OR, 8.3, P = 0.005; DQB1*03-DRB3*02: OR, 13.5, P = 0.001) but not among African American patients. Furthermore, although HLA DQB1*03, DRB1*11, and DRB3*02 genotypes were associated with increased HCV-specific CD4 T cell response in univariate analyses, these associations were lost when controlling for virological outcomes. CONCLUSION: We conclude that the immunogenetic basis for HCV clearance differs between ethnic groups and that the association between HLA class II and HCV clearance is not directly explained by antiviral CD4 T cell response.
UNLABELLED: The outcome of hepatitis C virus (HCV) infection has been associated with antiviral CD4 T cell response, human leukocyte antigens (HLA) class II genotypes, and ethnicity. However, HLA class II molecules restrict the nature of CD4 T cell response, and HLA distributions differ between ethnic groups. In this study, we asked whether HLA class II genotypes associated with HCV clearance are shared between Caucasian and African Americans and whether they contribute to enhanced antiviral CD4 T cell response. In a cohort of 93 HCV-seropositive subjects from Northeast America with defined ethnicity, virological outcome, and HCV-specific CD4 T cell proliferation, we confirm the previously reported associations between HCV clearance and two HLA types (DQB1*03, DRB1*11) while identifying a new association with DRB3*02. Strikingly, these associations were identified only among Caucasian [DQB1*03: odds ratio (OR), 10.4; P = 0.031, DRB1*11: OR, 7.0, P = 0.019; DRB3*02: OR, 8.3, P = 0.005; DQB1*03-DRB3*02: OR, 13.5, P = 0.001) but not among African American patients. Furthermore, although HLA DQB1*03, DRB1*11, and DRB3*02 genotypes were associated with increased HCV-specific CD4 T cell response in univariate analyses, these associations were lost when controlling for virological outcomes. CONCLUSION: We conclude that the immunogenetic basis for HCV clearance differs between ethnic groups and that the association between HLA class II and HCV clearance is not directly explained by antiviral CD4 T cell response.
Authors: T K Oleksyk; C L Thio; A L Truelove; J J Goedert; S M Donfield; G D Kirk; D L Thomas; S J O'Brien; M W Smith Journal: Genes Immun Date: 2005-06 Impact factor: 2.676
Authors: Kazushi Sugimoto; David E Kaplan; Fusao Ikeda; Jin Ding; Jonathan Schwartz; Frederick A Nunes; Harvey J Alter; Kyong-Mi Chang Journal: J Virol Date: 2005-06 Impact factor: 5.103
Authors: K R Reddy; J H Hoofnagle; M J Tong; W M Lee; P Pockros; E J Heathcote; D Albert; T Joh Journal: Hepatology Date: 1999-09 Impact factor: 17.425
Authors: Mark H Kuniholm; Andrea Kovacs; Xiaojiang Gao; Xiaonan Xue; Darlene Marti; Chloe L Thio; Marion G Peters; Norah A Terrault; Ruth M Greenblatt; James J Goedert; Mardge H Cohen; Howard Minkoff; Stephen J Gange; Kathryn Anastos; Melissa Fazzari; Tiffany G Harris; Mary A Young; Howard D Strickler; Mary Carrington Journal: Hepatology Date: 2010-05 Impact factor: 17.425
Authors: Edward L Murphy; Junyong Fang; Yongling Tu; Ritchard Cable; Christopher D Hillyer; Ronald Sacher; Darrell Triulzi; Jerome L Gottschall; Michael P Busch Journal: J Infect Dis Date: 2010-08-15 Impact factor: 5.226
Authors: Jane H Wang; Xin Zheng; Xiaogang Ke; M Tevfik Dorak; Jingjing Shen; Basmattee Boodram; Maurice O'Gorman; Kenneth Beaman; Scott J Cotler; Ronald Hershow; Lijun Rong Journal: Virol J Date: 2009-05-01 Impact factor: 4.099
Authors: M H Kuniholm; K Anastos; A Kovacs; X Gao; D Marti; A Sette; R M Greenblatt; M Peters; M H Cohen; H Minkoff; S J Gange; C L Thio; M A Young; X Xue; M Carrington; H D Strickler Journal: Genes Immun Date: 2013-05-02 Impact factor: 2.676